THE IN VITRO AND IN VIVO ACTIVITY OF STREPTOMYCIN AGAINST HEMOPHILUS PERTUSSIS

C. P. HEGARTY, ELIZABETH THIELE, AND W. F. VERWEY

Department of Bacteriology, Medical-Research Division, Sharp and Dohme, Inc., Glenolden, Pennsylvania

Received for publication August 11, 1945

Streptomycin (Schatz, Bugie, and Waksman, 1944) has been shown to be efficacious in the treatment of infections due to gram-negative bacteria (Jones et al., 1944; Robinson et al., 1944; Heilman, 1945; Reimann et al., 1945). A determination of the activity of streptomycin against Hemophilus pertussis seemed desirable since there is need for an effective agent to be used in the therapy of whooping cough.

IN VITRO ACTIVITY

The in vitro susceptibility of various strains of H. pertussis to streptomycin was determined by inoculating plates of Bordet-Gengou agar and tubes of a modified liquid Hornibrook medium (Hornibrook, 1939; Verwey and Sage, 1945) containing varying concentrations of the drug. The data are given in table 1. The 4 strains investigated were approximately equally susceptible to the drug, 3 \( \mu g \) per ml being bacteriostatic in Bordet-Gengou agar, slightly greater concentrations being required to prevent growth in the liquid medium.

To determine the bactericidal activity of streptomycin, modified Hornibrook's medium containing 15 \( \mu g \) of streptomycin per ml was prepared. Tubes were inoculated with the 4 strains of H. pertussis to give a concentration of 1 billion cells per ml. At intervals samples were removed, diluted beyond the bacteriostatic range of activity of streptomycin, and the viable cells determined by plate counts on Bordet-Gengou agar. No significant decrease in the number of viable cells was found after 6 hours' incubation at 37 °C; however, 99.75 per cent of the cells were nonviable after 30 hours. Control cultures without the drug grew normally. It is evident that streptomycin at a concentration of 15 \( \mu g \) per ml was bactericidal.

IN VIVO ACTIVITY

The in vivo activity of streptomycin against H. pertussis no. 18323 was determined by intracerebral infection of CFI mice, as suggested by Kendrick (1944), and intraperitoneal injections of the drug. Mice weighing from 14 to 16 grams were infected with 40,000 cells of H. pertussis contained in 0.04 ml prepared by suspending 24-hour growth on Bordet-Gengou agar plates in modi-

1 The activity of streptomycin is expressed in terms of the weight of the streptomycin base, one mg of which is equivalent to approximately 1,000 Escherichia coli dilution units of Waksman.

2 This strain was supplied through the courtesy of Dr. Pearl Kendrick of the Michigan State Department of Health.
bled Hornibrook's medium. Turbimetric methods were used to standardize the suspension, and the virulence of the strain was assayed by serial dilution of the challenge dose. Treatment with streptomycin was initiated immediately after infection, and 0.5 mg was administered intraperitoneally each day (0.125 mg every 6 hours) for a 5-day period. The infected controls received intraperitoneal injections of saline (table 2).

The mean survival time of the animals receiving saline was 3.9 days and was increased to 7.5 days for those receiving 0.5 mg of streptomycin per day. Streptomycin administered at this level markedly increased the survival time but did not protect the animals from ultimate death. The lone surviving mouse in the treated group was autopsied on the 15th day and H. pertussis was recovered from the brain. Virulence control mice infected with 1,250 bacteria died within 5 to 10 days with a mean survival time of 7.8 days, indicating that the infecting dose given the test animals contained at least 32 minimum lethal doses of H. pertussis organisms.

This investigation was extended by a series of experiments in which the infecting dose was decreased and the duration and the intensity of therapy were increased. Mice were infected with 5,000 organisms, and streptomycin was administered over a 10-day period at levels of 1.0 and 2.0 mg per day. Intra-
peritoneal injections of 0.25 and 0.5 mg of streptomycin were made every 6
hours.

As shown in table 3, streptomycin administered at a level of 2.0 mg per day
(150 mg per kg per day) protected 50 per cent of the mice against death. How-
ever, those that died had a mean survival time of 22 days, the first mortality
being on the 19th day. The dosage of 1.0 mg per day permitted 44.5 per cent
survival, and the mean survival time of the animals that died was 15.2 days.
Mice receiving saline all died between the 5th and 8th day, the mean survival
time being 5.5 days. An infecting dose of 312 cells of H. pertussis per mouse
caused death of 50 per cent of the animals with a mean survival time of 7.4
days. Cultures of H. pertussis were recovered from all animals that died during
these experiments. All surviving mice were autopsied and cultured on the
38th day after infection; attempts to isolate H. pertussis were unsuccessful, and
no gross pathological lesions were observed.

**TABLE 3**

<table>
<thead>
<tr>
<th>INFECTING DOSE OF H. PERTUSSIS</th>
<th>TREATMENT</th>
<th>NO. OF MICE</th>
<th>SURVIVAL IN DAYS</th>
<th>PER CENT MORTALITY</th>
<th>MEAN SURVIVAL TIME OF MICE THAT DIED</th>
</tr>
</thead>
<tbody>
<tr>
<td>5,000</td>
<td>2.0 mg per day</td>
<td>10</td>
<td>19, 20, 21, 27, 28, S, S, S, S, S†</td>
<td>50</td>
<td>22.0</td>
</tr>
<tr>
<td>5,000</td>
<td>1.0 mg per day</td>
<td>9*</td>
<td>5, 5, 16, 19, 31, S, S, S, S</td>
<td>55.5</td>
<td>15.2</td>
</tr>
<tr>
<td>5,000</td>
<td>Saline</td>
<td>10</td>
<td>5, 5, 5, 5, 5, 5, 5, 5, 6, S</td>
<td>100</td>
<td>5.5</td>
</tr>
<tr>
<td>5,000</td>
<td>None</td>
<td>10</td>
<td>3, 4, 4, 7, 19, S, S, S, S, S</td>
<td>50</td>
<td>7.4</td>
</tr>
</tbody>
</table>

* One mouse died 6 hours after infection because of an inoculation injury.
† S indicates survival for 38 days.

Cultures obtained from the brain of a mouse treated with 2.0 mg of strepto-
ymycin per day, and which died 28 days after infection, were tested for resistance
to streptomycin and were found to have the same in vitro susceptibility as the
original culture.

Streptomycin in dosages of 1.0 to 2.0 mg per day protected 50 per cent of the
mice and increased considerably the survival times of the animals that died.

These data indicate that further investigations concerning the therapeutic
role of streptomycin in H. pertussis infection are warranted.

**SUMMARY**

Streptomycin exhibited in vitro bacteriostatic activity against *Hemophilus pertussis* at a concentration of 3 μg per ml and was bactericidal at 15 μg per ml.

Infection of mice with 40,000 organisms and treatment with 0.5 mg of strepto-
ymycin per day for 5 days resulted in an average survival time approximately
twice that of the controls, but an ultimate mortality of 90 per cent of the animals.

Infection with 5,000 organisms and daily treatment with 2.0 mg of streptomy-
cin for 10 days protected 50 per cent of the mice. The mean survival time for those that died was 22 days as compared with 5.5 days for the controls.

Further investigations of the use of streptomycin in the therapy of *H. pertussis* infection are suggested.

**REFERENCES**


**Kendrick, Pearl.** 1944 Personal communication.


